



RECEIVED

JUL 23 2001

TECH CENTER 1600/2901

13/9
7/24/01
B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel E.H. Afar et al. Examiner: M. Davis
Serial No.: 09/389,000 Group Art Unit: 1642
Filed: August 31, 1999 Docket: G&C 129.27-US-U2
Title: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 16, 2001.

By: 

Name: Karen S. Canady

AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated February 14, 2001, please amend the above-identified application as follows. Please note that, in compliance with the new rules under 37 C.F.R. § 1.121, the amended paragraphs are presented in "clean" form with marked-up versions provided in the Appendix.

IN THE SPECIFICATION

Please amend the specification as follows:

At page 1, line 2, please insert the following paragraph:

a1
This application claims the benefit of United States provisional patent applications number 60/106,524, filed October 31, 1998, now abandoned, and number 60/098,610, filed August 31, 1998, the entire contents of each of which are incorporated herein by reference.